EXHIBIT 99


                               ONCOLOGIX TECH, INC
                              A Nevada Corporation

               AGREEMENT FOR THE EARLY RELEASE OF ESCROWED SHARES

The parties to this  Agreement are  Oncologix  Tech,  Inc, a Nevada  corporation
("the  Company")  and  each  of  the  following  (hereinafter  sometimes  called
individually a "Holder" and  collectively  "the Holders"):  Jeff Franco,  Andrew
Green, Andrew S. Kennedy, MD, and Adam Lowe. The parties have agreed as follows:


1. The Escrow

Each of the  Holders  is the  registered  owner of the  number  of shares of the
Company's common stock ("Shares") and the beneficiary of additional  Shares that
are being held in escrow, as shown in the following table:

             Name of Holder              Number of           Number of
                                         Shares in           Continuing
                                         Escrow *            Shares

          Jeff Franco                    8,369,842           5,579,896
          Andrew Green                   2,821,342             940,448
          Andrew S. Kennedy, MD          8,369,842           5,579,896
          Adam Lowe                      2,821,342             940,448


          * The  number  of  shares  shown  in the
          column  entitled  "Number  of  Shares in
          Escrow"  does  not  include  shares  not
          subject  to the Escrow  arrangement,  or
          shares previously held in the Escrow but
          released  pursuant to the terms thereof.
          Those never escrowed shares and released
          shares are shown in the adjoining column
          headed "Continuing Shares".


The Escrowed  Shares are being held in escrow  pursuant to that  certain  Escrow
Agreement among the parties dated July 26, 2006 ("The Escrow Agreement').  Under
the Escrow  Agreement,  the Escrowed  Shares would be released to the respective
Holders upon the occurrence of certain events, or would otherwise be returned to
the  Company  if those  events  did not  occur on or before  July 26,  2012 (the
"Benchmark  Date").  The parties  acknowledge that the events, the occurrence of
which were to result in the release of the Escrowed Shares to the Holders,  will
not occur prior to the Benchmark Date, and that the Escrowed Shares will,  under
the terms of the Escrow Agreement, be released to the Company on such date.


2. Purpose.

The  purpose  of this  Agreement  is to  provide  for the early  release  of the
Escrowed Shares to the Company, which will allow the Company, as the Company has
informed  the Holders to seek  additional  financing.  Accordingly,  each of the
Holders hereby  consents to the Escrow  Agent's  (Hodes,  Ulman,  Pessin & Katz,
P.A.) immediate release to the Company of their respective Escrowed Shares.

                                       1




3. Consideration - Reliance.

Each Holder  acknowledges  that after the return of the  Escrowed  Shares to the
Company,  he will continue to be a significant  shareholder of the Company as an
owner of the  "Continuing  Shares".  Based on such  continuing  ownership,  each
Holder may realize a significant  financial  benefit if the Company  succeeds in
its financing efforts.  Furthermore,  each Holder  acknowledges that the Company
and future  investors in the Company will rely on such return in calculating the
number of authorized but unissued shares of the Company's  common stock and that
such calculation will be the basis for financial statements filed by the Company
pursuant to the federal securities laws.


4. Instructions to Escrow Agent.

Each Holder  agrees that the delivery of a signed copy of this  Agreement  shall
constitute  instructions to the Escrow Agent, Hodes, Ulman, Pessin & Katz, P.A.,
to  release  all of the  Escrowed  Shares to the  Company.  Notwithstanding  the
foregoing,  however, each Holder also agrees to execute and deliver such further
instructions,  agreements or instruments  reasonably  required to give effect to
the agreements contained herein.



_________________________________   _____________________

Jeff Franco                         Date


_________________________________   _____________________

Andrew Green                        Date



_________________________________   _____________________

Andrew S. Kennedy, MD               Date



_________________________________   _____________________

Adam Lowe                           Date


                                       2